Article 1 to 1 out of 1 concerning Takeda Pharma AG
Swissmedic accepts Santhera's filing of SNT-MC17 in Friedreich's Ataxia(10/05/2007) Santhera Pharmaceuticals and Takeda Pharma AG announced that Swissmedic has accepted the filing of an application for authorization for Santhera's lead compound SNT-MC17 for the treatment of Friedreich's Ataxia (FRDA). SNT-MC17 has shown clinical ...
Top
